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Summary. Von Willebrand disease (VWD) is an
inherited bleeding disorder caused by the quantitative or
qualitative deficiency of von Willebrand factor (VWF).
Replacement therapy with plasma-derived VWF/factor
VIII (FVIII) concentrates is required in patients
unresponsive to desmopressin. To assess the efficacy,
safety and ease of use of a new, volume-reduced (VR)
formulation of VWF/FVIII concentrate Haemate® P in
patients requiring treatment for bleeding or prophylaxis
for recurrent bleeding or for invasive procedures.
Pharmacoeconomic variables were also recorded. Data
were analysed using descriptive statistics. This was a
multicentre, prospective, observational study. Consecutively
enrolled patients received Haemate® P VR according to
their needs, and were followed for 24 months. Of the 121
patients enrolled, 25.6% had type 3 VWD and more
than 40% had severe disease. All patients were
followed for 2 years, for a total of 521 visits. On-
demand treatment was given to 61.9% of patients,
secondary long-term prophylaxis to 25.6% and
prophylaxis for surgery, dental or invasive procedures
to 45.5%. The response to treatment was rated as good
to excellent in >93–99% of interventions. The new
formulation was well tolerated by all patients with no
report of drug-related adverse events. The switch to
volume-reduced Haemate® P was easy to perform and
infusion duration was decreased twofold compared
with the previous formulation. Volume-reduced
Haemate® P was at least as effective and well-tolerated
as the previous formulation.
Keywords: formulation switch, Haemate P, observational
study, pasteurized VWF/FVIII concentrate, volume-
reduced infusion, von Willebrand disease
Introduction
Von Willebrand disease (VWD), an inherited bleeding
disorder which affects 1–2% of the general population
[1–3], is caused by a deficiency or abnormality of the
von Willebrand factor (VWF), a multimeric adhesive gly-
coprotein with a key role for platelet adhesion to occur
[3]. The VWF is also the carrier of factor VIII (FVIII),
and therefore indirectly contributes to coagulation [3].
The treatment of VWD aims to correct both abnor-
mal platelet adhesion and FVIII deficiency [1] and it can
be administered on demand or as prophylaxis in the
more severe forms of the disease to control recurrent
mucosal and joint bleeding or in the case of invasive
procedures [4,5].
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Therapy with desmopressin and replacement ther-
apy with plasma-derived VWF or VWF/FVIII concen-
trates are the mainstay of VWD treatment [4].
Haemate® P (CSL Behring, Marburg, Germany), a
pasteurized VWF/FVIII plasma-derived concentrate in
use for almost three decades, has been demonstrated
by extensive clinical practice to be an effective and
safe treatment for patients with VWD [6,7]. A novel,
volume-reduced formulation has been recently devel-
oped, maintaining the same characteristics, but with a
reduction of 50% of reconstitution volume which
could be useful especially when a high dose of VWF/
FVIII is required in a single infusion [7]. Clinical expe-
rience with this novel formulation is limited, and addi-
tional information is desirable for a complete
evaluation of its efficacy and safety.
To monitor the impact of the switch to this novel
concentrate formulation in the context of real-life clin-
ical practice, a prospective, observational study involv-




This survey was a prospective, observational, open-
label study conducted in HTCs located throughout
Italy. The objectives of the study were: (i) to monitor
clinical efficacy and tolerability during the switch to
the volume-reduced VWF/FVIII formulation; (ii) to
evaluate prospectively the incidence of spontaneous
bleeds and their management in a large population of
patients with VWD; (iii) to collect data for pharmaco-
economic analysis; and (iv) to compare the ease of use
of the old and the new formulations.
Patient enrolment took place between 2007 (year of
introduction of the new formulation) and 2008.
Patients were observed for 24 months. The 24-month
follow-up started after the administration of the first
infusion of the volume-reduced formulation of the
VWF/FVIII concentrate. The study was non-interven-
tional and patients were treated with volume-reduced
Haemate® P VR (CSL Behring Marburg, Germany)[8]
based on their clinical needs, as judged by the investiga-
tor. The study was performed in accordance with the
Declaration of Helsinki, and its design was approved by
local Ethical Committees. All patients provided written
consent to their inclusion in the study.
Study population
Patients with VWD of either gender and of any age
were eligible if they had been already treated with
Haemate® P. Patients were diagnosed according to the
criteria of the Scientific Standardization Committee on
VWF of the International Society of Thrombosis and
Haemostasis, and VWD types were determined as pre-
viously reported [1,9].
Treatment
Patients received Haemate®P VR (vials of 500/1200 or
1000/2400 IU of FVIII/VWF:Ristocetin Cofactor
(VWF:RCo) to be reconstituted with 10 mL instead of
20 mL or 15 mL instead of 30 ml infusion solution
respectively) intravenously. Investigators were asked
to follow current treatment guidelines [1,4] and the
doses recommended by the manufacturer (VWF:RCo,
40–80 IU kg1 body weight and FVIII:C, 20–40 IU kg1
body), but no restriction to the investigators’ clinical
decision was made [8]. The concentrate was given for
three distinct situations: (i) as treatment on demand
for bleeding episodes; (ii) as secondary long-term pro-
phylaxis; and (iii) as prophylaxis for surgery, dental
or invasive procedures. Major surgery was defined as
surgery under general anaesthesia and requiring
>4 days of hospitalization.
Variables recorded
Each patient was evaluated at the enrolment visit
(baseline) and during at least one but not more than
four follow-up visits per year. In each centre, all visits
were performed by the same trained clinician, to limit
inter-operator variability.
Demographic characteristics (including VWD type
and gene mutation were available) and detailed medical
history (including date of first VWD diagnosis, bleeding
history and bleeding score [BS] measured as previously
reported [10], bleeding frequency during the last
12 months, previous treatments, total exposure days
[ED] to VWF/FVIII concentrates) were collected at en-
rolment. Increased disease severity correlates with
increasing BS: healthy individuals have scores <3,
whereas BS  3 and <5 indicates mild disease, BS  5
and <10 indicates moderate disease and BS  10 indi-
cates severe disease [10]. At each follow-up visit, the
clinical response to Haemate® P was assessed by the cli-
nician as recommended by the European Medicines
Agency Guideline on the clinical investigation of
human plasma-derived VWF products and rated as pre-
viously reported [9,11]. The response was rated as
excellent when it was clinically not different from nor-
mal on surgery and invasive procedures, or when opti-
mal and fast control of spontaneous bleeding was
achieved; good, when mildly abnormal, partial or
delayed control of spontaneous bleeding, or slight tran-
sient oozing from surgical wounds; moderate, when
moderately abnormal haemostasis bleeding not fully
controlled but no need for additional therapy; poor,
when no improvement at all with continuation of
bleeding and need for additional or alternative thera-
pies [9]. The safety of the treatment was also monitored
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and suspected adverse events related to the treatment
were recorded in a standardized case report form.
Adverse events were defined as any change from baseline
in the patient’s health status that occurred within 24 h
of the VWF/FVIII concentrate administration. Addi-
tional data, including laboratory tests and pharmacoeco-
nomic variables (work/school days lost; hospitalization;
interventions required for the management of haemor-
rhagic complications) were recorded when available.
Statistical methods
All data were analysed using descriptive statistics. A
prespecified ad interim analysis was planned and con-
ducted on the first 50 patients for whom the data
from at least one follow-up visit were available [12].
Results
Characteristics of the study population
Demographic and baseline clinical characteristics. In
total, 121 patients were enrolled in the study and all
were followed-up for 24 months after inclusion. Their
baseline characteristics are summarized in Table 1.
Type 1 VWD was most prevalent (56/121, 46.3%),
followed notably by type 3 VWD (31/121, 25.6%),
type 2B (22/121, 18.2%), type 2A (8/121, 6.6%) and
type 2M (1/121, 0.8%) [data on VWD type not avail-
able for three (2.5%) patients]. At the time of their
first study visit, the majority of patients (83.5%) were
receiving Haemate® P on-demand, whereas 13.2%
received it for long-term secondary prophylaxis. The
median BS was high (severe disease) and homogenous
across VWD subtypes (median score of study cohort
was 15, range 2–36). Forty-three per cent of patients
had VWF:RCo <10 IU dL1 (indicative of severe dis-
ease) and in 48.8% of patients FVIII:C was
 20 IU dL1 (also indicative of severe disease).
Treatment history. For 61% of the study cohort, on-
demand Haemate® P had been the only treatment
modality, whereas a minority (6%) had received only
prophylactic Haemate® P. About one-third of the
cohort (33%) had received treatment both on demand
and as prevention (Table 1). Total ED to Haemate®
P up to the first study visit varied among patients,
with a tendency to more limited exposure in patients
with VWD type 1 compared with the other disease
types (> 70% of type 1 patients with ED 1–24 days).
During the last 12 months before entering the study,
42 patients of the entire cohort (34.7%) underwent
surgery, dental extractions and invasive procedures,
with a clinical response scored as excellent or good in
95% of cases [9]. In the same period, the majority of
patients (75.2%) had either no bleeding episodes or
<5 episodes requiring treatment with VWF/FVIII con-
centrates. Epistaxis occurring in 77.7% of patients
was the most frequent spontaneous haemorrhagic
event, followed by gingival bleeding (54.5%).














Male 23 (41.1%) 5 (62.5%) 10 (45.5%) 1 (100%) (–) 12(38.7%) 53 (43.8%)
Female 33 (58.9%) 3 (37.5%) 12 (54.5%) – 19 (61.3%) 68 (56.2%)
Age, years, median [range] 48.5 [5–79] 41.5 [21–71] 30.0 [9–61] 68.0 [–] 31.0 [1–73] 41.0 [1–79]
Diagnostic tests, IU dL1, median [range]
VWF:RCo 12.8 [<6–50]‡ 8 [<6–35] 10 [<6–28] 8 <6 [<6–8]‡ 8 [<6–50]
FVIII:C 36 [3–89.7] 42 [8.7–85] 27 [18–58] 110 [–] 5 [0.3–26.8] 20.35 [3–110]
VWF:Ag 23 [6–55] 31 [10–58] 36 [26 –81] 116 [–] 1 [1–12] 12.15 [1–116]
Type of treatment with Haemate® P*
On-demand 52(92.9%) 7 (87.5%) 17(77.3%) 1(100%) 21(67.7%) 101(83.5%)
Prophylaxis 2 (3.6%) 1 (12.5%) 4 (18.2%) 0 (0%) 9(29%) 16(13.2%)
Not available 2 (3.6%) 0 (0%) 1 (4.5%) 0 (0%) 1 (3.2%) 4 (3.3%)
Bleeding score, median [range] 14 [2–29] 14.5 [7–25] 20 [7–32] 21 [–] 18 [4–36] 15 [2–36]
Patients with total ED to VWF/FVIII concentrates
1–4 12 (21.4%) 2 (25%) 3 (13.6%) – 5 (16.1%) 23 (19%)
5–24 31 (55.4%) 1 (12.5%) 3 (13.6%) – 5 (16.1%) 41 (33.9%)
25–49 3 (5.4%) 1 (12.5%) 1 (4.5%) – 2 (6.5%) 7 (5.8%)
50– 150 10 (17.9%) 4 (50%) 14 (63.6%) 1 (100%) 19 (61.3%) 48 (39.7%)
NA 0 (0%) 0 (0%) 1 (4.5%) – 0 (0%) 2 (1.7%)
Patients with bleedings during last 12 months†
0 – 4 bleeds 48 (85.7%) 7 (87.5%) 15 (68.2%) – 19 (61.3%) 91 (75.2%)
5 – 19 2 (3.6%) 1 (12.5%) 7 (31.8) 1 (100%) 8 (25.8%) 20 (16.5%)
20 – 50 1 (1.8%) – – – 4 (12.9%) 5 (4.1%)
NA 5 (8.9%) – 5 (4.1%)
*Bleedings requiring treatment with VWF/FVIII concentrates.
†At presentation/study entry.
‡Some patients on prophylaxis at time of enrolment.
§VWD type not available for three patients.
ED, days of exposure.
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Switch to Haemate® P VR. A total of 521 follow-up
visits took place during the 24 months of observation.
The concentrate was administered in 44% of these
visits by hospital staff, whereas in only 20% of the
visits was the concentrate self-administered by the
patient. Handling of the new concentrate formulation
was easy and required a median time of 10 min both
for reconstituting the concentrate and for injecting it
(approximately half the time normally required for
infusion of the previously available formulation).
Haemate® P VR was given on demand to 61.9% of
all patients (75/121), as secondary prophylaxis to
25.6% (31/121) and for surgical, dental or invasive
procedures to 45.5% (55/121).
Treatment on-demand. Of the 75 patients who were
given volume-reduced Haemate® P on demand, 49
received only this treatment modality whereas 26
received also long-term prophylaxis. The data regard-
ing on-demand treatment are summarized in Table 2.
A total of 677 bleeding events (median four events/
patient, range 1–55) were treated with a total of 1495
infusions (median 13 infusions/patient, range 1–121).
The median number of infusions required for each
event was one (range 1–28). The response to Hae-
mate® P was excellent in 316 treatments (46.9%),
good in 327 (48.5%), moderate in 25 (3.7%), whereas
no response was reported in one case (0.1%)
[response data not available for 5 (0.7%) patients]. Of
the 677 bleeding episodes recorded in patients treated
on-demand, the most frequent were epistaxis (203/
677, 30%) followed by gingival bleeding (126/677,
18.6%), bleeding in joints (119/677, 17.6%), menor-
rhagia (104/677, 15.4%) and gastrointestinal bleeding
(64/677, 9.5%).
Secondary long-term prophylaxis. The patients receiv-
ing prophylactic treatment with Haemate® P VR (31/
121, 25.6%) had a total of 127 events during the
24 months of follow-up (median three events per
patient, range 1–11). The data regarding this treatment
modality are shown in Table 3. A regimen of
20 IU kg1 FVIII twice or thrice weekly was used in
about 90% of cases. The total number of infusions was
2850 and the median number of infusions per patient
was 63 (range 6–308; median of 22 infusions per event,
range 1–104). Each patient received 112 9 103 IU
Haemate® P (median value, range 9–843 9 103 IU).
The most frequent reasons that prompted the initiation
of prophylaxis were prevention of bleeding in joints
(41 events), gastrointestinal bleedings (34 events) and
menorrhagia (17 events) (Fig. 1). Overall, the response
to treatment was good to excellent in 118/127 (92.9%)
cases whereas in only 6/127 (6.3%) was the response
rated as moderate and poor (Table 4).
Prophylaxis for surgery, dental extractions, invasive
procedures. During the 24-month observation, 55
patients underwent surgery, dental extractions and
other invasive procedures (total number of interventions,
Table 2. On-demand treatment*: characteristics of therapeutic interventions with Haemate® P VR in the overall study cohort and according to VWD types.
Type 1 Type 2A Type 2B Type 2M Type 3 Total
N. receiving on-demand treatment 29 (38.7%) 5 (6.7%) 14 (18.7%) 1 (1.3%) 25 (33.3%) 75 (100%)
Total events 131 17 150 10 365 674*
Events per patient, median [range] 2 [1–40] 3 [1–6] 7.5 [2–39] 10 6 [1–55] 4 [1–55]
Infusions per event, median [range] 1 [1–26] 2 [1–18] 2 [1–12] 3 [1–14] 1 [1–28] 1 [1–28]
Clinical response
Excellent 95 (72.5%) 9 (52.9%) 87 (58%) 10 (100%) 115 (31.5%) 316 (46.9%)
Good 36 (27.5%) 7 (41.2%) 55 (36.7%) – 228 (62.5%) 327 (48.5%)
Moderate/Poor – – 6 (4%) – 20 (5.5%) 26 (3.8%)
NA – 1 (5.9%) 2 (1.3%) – 2 (0.5%) 5 (0.7%)
*Total number of events treated was 677, but for three events disease type was unknown.
Table 3. Prophylaxis: characteristics of therapeutic interventions with Haemate® P VR in the overall study cohort and according to VWD types.
Type 1 Type 2A Type 2B Type 3 Total
N. receiving prophylaxis 9 (29%) 1 (3.2%) 5 16.1%) 16 (51.6%) 31 (100%)
Total events 25 10 29 63 127
Events per patient, median [range] 2 [1–5] 10 5 [2–10] 2 [1–11] 3 [1–11]
Total infusions 680 308 404 1458 2850
Infusions per patient, median [range] 42 [26–244] 308 63 [21–185] 88.5 [6–207] 63 [6–308]
Infusions per event, median [range] 19 [3–84] 31 [16–61] 18 [3–50] 24 [1–104] 22 [1–104]
Haemate® P per event, IU 9 103, median [range] 42 [6–168] 74 [32–169] 24 [6–150] 22 [3–144] 30 [3–169]
Clinical response
Excellent 12 (48%) 3 (30%) 13 (44.8%) 21 (33.3%) 49 (38.6%)
Good 13 (52%) 6 (60%) 14 (48.3%) 36 (57.1%) 69 (54.3%)
Moderate/Poor – 1 (10%) 2 (6.9%) 5 (7.9%) 8 (6.3%)
NA – – – 1 (1.6%) 1 (0.8%)
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126) and therefore received Haemate® P VR as short-
term prophylaxis. The procedures were mostly den-
tistry interventions (52.1%) and invasive procedures/
endoscopy (25.6%). The concentrate (infusion of
4 9 103 IU per event, median; 12 9 103 IU per
patient, median) was given 60 min (median) before
the procedure and after surgery (timing of postopera-
tive treatment was dependent on surgery type and
patient bleeding tendency) [Table 4]. These patients
received a total of 234 postoperative, surgery-related
infusions (median 7.0 per patient, range 1–19). The
median number of postoperative infusions required to
treat one event was five (range 1–16). In this
subgroup of patients, most events were treated suc-
cessfully with a response rated as excellent in 56.7%
of the events treated (only one patient, with VWD
type 2A, had a moderate response to treatment)
[Table 4].
Tolerability and safety of the switch. The treatment
with Haemate® P was generally well-tolerated during
the 24-month observation after the switch to the vol-
ume-reduced formulation of Haemate® P. There were
no reports of adverse reactions related to the study
drug or development of inhibitors against VWF in the
entire population, including patients on secondary
prophylaxis and thus receiving more infusions. No
thrombotic events were reported.
Impact of VWD on patient productivity and resource
use. During the 24-month follow-up period, almost
half of the patients missed days at school/work
because of VWD, 36.4% were hospitalized and
35.5% underwent surgery because of the disease
(Table 5).
Discussion
The efficacy and safety of Haemate® P for the treat-
ment of VWD in a setting of real-life clinical practice
have so far been addressed in a number of retrospec-
tive and prospective studies [9,13–17]. To our knowl-
edge, however, this is the first prospective study on a
large (121 patients) population of patients with VWD
receiving Haemate® P to treat a bleeding episode, as
long-term prophylaxis or as short-term prophylaxis
for surgery. Treatment history and dosing information
was very detailed, and data on patients undergoing
surgery/invasive procedures, a treatment setting still
under intense investigation, were also collected. Also,
the population considered was quite unique in terms
of VWD-type distribution, as a relatively high propor-
tion of patients had disease type 3 (31/121), a low
prevalence subgroup in the general population of
patients with VWD and most severely predisposed to
bleeding events due to the virtual absence of VWF
[2,3]. The study population was also assessed in terms
of BS, a parameter useful for the objective assessment
of disease severity and for guiding therapeutic choices.
The high average BS observed clearly indicates that
a large proportion of the recruited patients had a
Table 4. Characteristics of therapeutic interventions with Haemate® P VR in the patients who underwent surgery, dental extractions or other invasive
procedures.
Type 1 Type 2A Type 2B Type 2M Type 3 Total
N. receiving treatment 26 (47.3%) 6 (10.9%) 8 (14.5%) 1 (1.8%) 12 (21.8%) 55* (100%)
Total events 70 10 18 2 20 127
Events per patient,
median [range]
1.5[1–12] 1[1–4] 1[1–6] 2 1 [1–4] 1 [1–12]
Infusions per event†,
median [range]
3.5 [1–12] 14 [2–16] 5.5 [2–12] 14 6.5 [3–12] 5 [1–16]
VWF:RCo, IU kg1 day1,
median [range]






*Including two patients with unknown disease type.
†Only postoperative infusions.
‡Based on 102 clinical response evaluation sheets.









Fig. 1. Events leading to the decision to give prophylactic Haemate® P to
the patients in the subgroup treated with prophylaxis.
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significant bleeding tendency, thus strengthening the
relevance of the observed results.
One of the objectives of the study was to monitor
the efficacy of a new volume-reduced formulation of
Haemate® P, introduced in 2007. The treatment with
this formulation was proved effective overall in the
three treatment modalities considered, and the major-
ity of patients including patients with type 3 VWD
achieved haemostatic responses rated as ‘good’ to
‘excellent’, with no significant differences between dis-
ease subtypes. These results confirmed those of a pre-
planned ad interim analysis of the study [12]. The
new formulation was therefore at least as effective as
the previous one, also associated with clinical
responses rated excellent/good in the majority of
patients [9,13–17]. Our efficacy findings were also in
line with those of recently published studies with
other commercially available VWF/FVIII concentrates
[18–20].
During the 24-month follow-up period, there was
an increase in the number of patients receiving Hae-
mate® P VR for long-term prophylaxis (n = 31) com-
pared with those on prophylaxis at baseline (n = 16).
The role of prophylaxis with VWF/FVIII concentrates
in VWD is still a matter of debate. So far, few studies
have evaluated the use of secondary prophylaxis in
VWD. [21–27]. In the study by Berntorp et al. [23] in
35 patients with VWD, mostly with type 3 VWD,
prophylaxis was associated with a substantial decrease
in the annual number of bleeding events [23,24].
Also, patients who started prophylaxis at a young age
had no joint bleeds and no clinical signs of arthropa-
thy. Similar results were obtained in a recently pub-
lished cohort study in 32 patients with a median
prophylaxis duration of 3 years leading to the resolu-
tion of recurrent bleeding in 31 of the 32 patients
[21]. Our results show that prophylactic treatment
with Haemate® P VR, both for short-term and long-
term bleeding prevention, was effective across all dis-
ease subtypes.
To our knowledge, the treatment of VWD has not
been evaluated in pharmacoeconomic analysis so far.
This type of analysis is strongly needed and is likely
to contribute also to establishing the role of long-
term prophylaxis in the treatment of VWD. We thus
collected data describing the impact of VWD on a
set of pharmacoeconomic variables. During the 24-
month follow-up almost half of the patients lost days
of school or work and about one-third was hospital-
ized because of the disease, whereas another third
underwent invasive procedures made necessary by the
condition. As no previous studies have addressed this
aspect it is difficult to make any comparison.
However, these figures are in keeping with the pres-
ence of significant bleeding histories and morbidity,
as shown by the high average BS observed at
enrolment.
Haemate® P VR was well-tolerated and the switch
to this new formulation was not associated with any
serious or unexpected adverse event, including throm-
boembolic events or inhibitor development, in agree-
ment with previous findings [12]. Thus, the new
formulation had a safety profile at least as favourable
as the previous one [9,13–17], in all treatment set-
tings, regardless the disease subtypes.
The average time required for infusion was, as
expected, approximately twofold shorter than the pre-
vious formulation and thus, it is particularly conve-
nient in those patients requiring a high dose in a
single infusion, or repeated infusions. The concentrate
was still mostly injected by hospital staff, but the
increased ease of use of the new formulation will
encourage patient self-administration. Time and effort
should be dedicated to patients and caregivers’ educa-
tion to home treatment, which enables a prompt and
more effective treatment of bleeding episodes and
facilitates implementation of prophylaxis, as widely
shown in haemophilia patients. [28,29] The diffusion
of treatment self-administration at home is likely to
improve the quality of life of patients with VWD,
which is significantly worse than that of the general
population as shown by a recent study in over 500
patients with VWD [30]. Ongoing studies are analy-
sing the cost-effectiveness of this VWF/FVIII concen-
trate formulation, particularly in the setting of
prophylactic treatment.
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